• Breast cancer in post-menopausal women
    • As an adjuvant treatment:
      • 1mg OD *5 years
    • As first-line treatment:
      • 1mg OD until tumor progression

Tablet: 1mg

It can be taken with or without food

Selective nonsteroidal aromatase inhibitor anticancer

It prevents conversion of androstenedione to estrone and estradiol in peripheral tissues thereby significantly lowering serum estradiol concentrations. There is no effect on adrenal corticosteroids or aldosterone

  • Hot flashes
  • Asthenia
  • Pain
  • Arthralgia
  • Arthritis
  • Nausea
  • Vomiting
  • Headache
  • Pharyngitis
  • Depression
  • Rash
  • Hypertension
  • Lymphedema
  • Insomnia
  • Edema
  • Weight gain
  • Dyspnea
  • Abdominal pain
  • Constipation
  • Hypercholesterolemia
  • Osteoporosis
  • Fractures
  • Cough
  • Bone pain
  • Diarrhea
  • Breast pain
  • Paresthesia
  • Infection
  • Cataracts
  • Myalgia
  • Thromboembolism
  • Angina
  • Hypersensitivity to components
  • Pregnancy
  • Breastfeeding during treatment and for at least 15 days after discontinuation
  • Premenopausal patients
  • Estradiol
  • Estrogen
  • Tamoxifen
  • Ethinylestradiol
  • Estropipate

                          Drug Status

Availability Prescription only
Pregnancy Category X
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Anastrozole 1mg Tablet 30’s Sandoz GMBH Novartis Kenya
Anastrozole Denk 1mg Tablet 30’s Laborex Kenya Denk Pharma
Anatero 1mg Tablet 10’s Hetero Labs Unisel Ltd
Arimidex 1mg Tablet 28’s AstraZeneca AstraZeneca
Womazol 1mg Tablet 10’s PSM Pharma PSM Pharma